

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Good Samaritan Hospital</p> <p>2. 520 S 7th St. Vincennes, IN 47591</p>	<p>In accordance with letter dated October 15, 2018.</p> <p>3. License number: 13-01787-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: February 28, 2026</p> <p>5. Docket No.: 030-01600 Reference No.:</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Cesium-137 permitted by 10 CFR 35.400</p> <p>E. Iridium-192 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (AEA Technology, Model CDC.T1 (J Series Tube Source); Isotope Products Laboratories, Model 6510 and 6515)</p> <p>E. Sealed Sources (Best Medical International, Model 81-01)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p> <p>D. 1.1 curies total</p> <p>E. 1.1 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> <p>E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-01787-01

Amendment No. 84

Docket or Reference Number
030-01600

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| F. Strontium-90 permitted by 10 CFR 35.400 | F. Sealed Sources (Amersham Corp., Model SIA.20) | F. 1.1 curies total | F. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Strontium-90 permitted by 10 CFR 35.400 | G. Sealed Sources (Mallinckrodt, Model 690) | G. 200 millicuries total | G. For storage only, incident to disposal. |

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 520 S 7th St., Vincennes, Indiana, 47591.
11. The Radiation Safety Officer (RSO) for this license is Mark Beanblossom.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|---|
| David Ray Alexander, M.D. | 10 CFR 35.100 and 35.200 |
| Jayant Amberker, M.D. | 10 CFR 35.200 |
| Marc Angelo Apostol, M.D. | 10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less) |
| David M. Ayoub, M.D. | 10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV) |
| Rebecca Miller Baggett, M.D. | 10 CFR 35.100 and 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-01787-01

Amendment No. 84

Docket or Reference Number
030-01600Authorized User(M.D.,D.O.,etc.)Material and Use

Tamara Jean Boore, M.D.

10 CFR 35.100 and 35.200

Tae Chung, M.D.

10 CFR 35.300 and 35.400

April L. Cox, D.O.

10 CFR 35.100 and 35.200

John Gilbert Felker, M.D.

10 CFR 35.100 and 35.200

Brian Gebhardt, M.D.

10 CFR 35.400

Robert Karl Haag, M.D.

10 CFR 35.100 and 35.200

Chester E. Harrison, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Nicholas L. Hilpiper, M.D.

10 CFR 35.100 and 35.200

Robert R. Knudson, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV)

Charles Eugene Neal, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV)

Robert B. Nordstrom, M.D.

10 CFR 35.100 and 35.200

Gerald Terhahn Riley, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Roger Robison, M.D.

10 CFR 35.300 and 35.400

Alexander T. Ryan, M.D.

10 CFR 35.100 and 35.200

Jennifer Lorraine Sharp, M.D.

10 CFR 35.100 and 35.200

Stephanie H. Swope, M.D.

10 CFR 35.100 and 35.200

Adam W. Taves, M.D.

10 CFR 35.100 and 35.200

Ryan R. Watson, M.D.

10 CFR 35.100 and 35.200

Ken William Winkler, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-01787-01Docket or Reference Number
030-01600


Amendment No. 84

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated February 20, 2015 (ML16058A678)
- B. Letter received August 28, 2015 (ML15240A388)
- C. Letter dated August 22, 2016 (ML16243A320)
- D. Letter received November 28, 2016 (ML16334A314)
- E. Letter dated January 27, 2017 (ML17033B560)

Date: JAN 16 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: 
Cassandra F. Frazier
Region 3